Ergothioneine mitigates cisplatin-evoked nephrotoxicity via targeting Nrf2, NF-κB, and apoptotic signaling and inhibiting γ-glutamyl transpeptidase

Life Sci. 2021 Aug 1:278:119572. doi: 10.1016/j.lfs.2021.119572. Epub 2021 May 6.

Abstract

Aim: Cisplatin is a potent chemotherapeutic agent whose therapeutic application is hindered by the associated nephrotoxicity. Cisplatin-evoked nephrotoxicity has been largely attributed to the induction of oxidative stress and inflammatory responses. The current study aimed at investigating the ability of ergothioneine to mitigate cisplatin-evoked nephrotoxicity and to elucidate the underlining molecular mechanisms.

Main methods: Wistar rats were treated with a daily dose of ergothioneine (70 mg/kg, po) for fourteen days and a single dose of cisplatin (5 mg/kg, ip) on day ten. On day fifteen, kidneys and blood specimens were collected and subjected to Western blotting, ELISA, histopathological, and spectrophotometric analysis.

Key findings: Ergothioneine significantly enhanced renal function in cisplatin-treated rats as manifested by increased GFR and decreased serum creatinine and blood urea nitrogen. Ergothioneine effectively reduced the cisplatin-induced oxidative stress and mitigated apoptosis and the histopathological changes. Mechanistically, ergothioneine induced the expression of the antioxidant transcription factor Nrf2 and up-regulated its downstream targets NQO1 and HO-1. Equally important, ergothioneine inhibited γ-glutamyl transpeptidase that plays crucial roles in biotransformation of cisplatin into a toxic metabolite. Additionally, it reduced the pro-apoptotic protein p53 and the inflammatory transcription factor NF-κB along with its downstream pro-inflammatory cytokines TNF-α and IL-1β.

Significance: The results of the current work shed the light on the ameliorating effect of ergothioneine on cisplatin-evoked nephrotoxicity that is potentially mediated through modulation of Nrf2, p53, and NF-κB signaling and inhibition of γ-glutamyl transpeptidase. This findings support the potential application of ergothioneine in controlling cisplatin-associated nephrotoxicity although clinical investigations are warranted.

Keywords: Cisplatin; DNA fragmentation; Ergothioneine; GGT; Nephrotoxicity; Nuclear factor kappa B.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antioxidants / pharmacology
  • Apoptosis
  • Caspase 3 / metabolism
  • Cisplatin / pharmacology*
  • DNA Fragmentation
  • Ergothioneine / pharmacology*
  • Kidney / drug effects*
  • Male
  • NF-E2-Related Factor 2 / metabolism*
  • NF-kappa B / metabolism*
  • Oxidative Stress
  • Rats
  • Rats, Wistar
  • Signal Transduction
  • Tumor Suppressor Protein p53 / metabolism
  • Up-Regulation
  • gamma-Glutamyltransferase / antagonists & inhibitors*
  • gamma-Glutamyltransferase / metabolism

Substances

  • Antineoplastic Agents
  • Antioxidants
  • NF-E2-Related Factor 2
  • NF-kappa B
  • Nfe2l2 protein, rat
  • Tp53 protein, rat
  • Tumor Suppressor Protein p53
  • Ergothioneine
  • gamma-Glutamyltransferase
  • Caspase 3
  • Cisplatin